On March 15, 2018, at Tencent AI Lab's second academic forum, Yao Xing, Vice President of Tencent, introduced Tencent’s three strategic directions in artificial intelligence: Pave the way for general artificial intelligence; set up a robot laboratory named "ROBOTICSX"; focus on a strategic presence of artificial intelligence in the medical industry. At the meeting, Yao Xing said that artificial intelligence (AI) is still at an early stage with single commercial penetration rate and narrow product design portfolio. In view of this, Tencent will take developing general artificial intelligence as the position of its future AI strategy.

At the same time, Tencent AI Lab plans to forge a strategic partnership with NATURERSEARCH, a subsidiary of Germany's Springer Nature. Going forward, the two sides will team up on studying the application of "AI+ medical care" and advancing the implementation of related products to offer solutions to some medical problems. In fact, in August 2017, Tencent already released its first AI-enabled medical product "Tencent MIAIS", which can screen esophageal cancer, pulmonary nodules, diabetes and other diseases with high accuracy. At present, the product has been applied in more than 100 3A hospitals across the country.